Gujarat Kidney & Super Speciality

Details of Gujarat Kidney & Super Speciality Limited IPO : Lot Size, Check Issue Date, Price

Gujarat Kidney & Super Speciality IPO Price: ₹108 to ₹114 per share

IPO Dates: 22nd December 2025 – 24th December 2025

Gujarat Kidney & Super Speciality

Company Overview

Incorporated in 2019, Gujarat Kidney and Super Speciality Limited (GKASSL) is a multispeciality healthcare provider offering secondary and tertiary care services across multiple locations in Gujarat, India.

Hospital Network & Infrastructure

The company operates seven multispeciality hospitals and four pharmacies, with:

  • Total bed capacity: 490 beds
  • Approved bed capacity: 455 beds
  • Operational bed capacity: 340 beds

Hospital Locations

GKASSL’s hospital network includes:

  • Gujarat Kidney and Superspeciality Hospital, Vadodara
  • Gujarat Multispeciality Hospital, Godhra
  • Raj Palmland Hospital Private Limited, Bharuch
  • Surya Hospital and ICU, Borsad
  • Gujarat Surgical Hospital, Vadodara
  • Ashwini Medical Centre, Anand

The company also operates Ashwini Medical Store in Anand.

Healthcare Services Offered

Secondary Care Services

  • General medical treatments
  • Surgical procedures

Tertiary Care Services

  • Super speciality surgical procedures

Clinical Specialities

Gujarat Superspeciality Hospital provides treatment across multiple specialities, including:

  • Internal medicine
  • General surgery
  • Minimally invasive procedures
  • Orthopaedics and trauma care
  • Joint replacement surgery
  • Obstetrics and gynaecology
  • Respiratory care
  • Non-interventional cardiology
  • Diabetology
  • Anaesthesiology

Medical & Support Staff

As of June 30, 2025, the company employed:

  • 89 doctors
  • 332 nurses
  • 338 other staff members

Competitive Strengths

  • Strong presence in renal sciences, with established sub-specialities in urology
  • Asset-light business model focused on central Gujarat
  • Ability to attract and retain skilled medical professionals
  • Proven track record of operational and financial growth

Bidding Starts In

Gujarat Kidney & Super Speciality IPO Specifics:

IPO DateMon, Dec 22, 2025 to Wed, Dec 24, 2025
Face Value₹2 per share
Price Band₹108 to ₹114 per share
Lot Size128 Shares
Sale TypeFresh Capital
Total Issue Size1,84,89,583 shares
2,20,00,000 shares
(aggregating up to ₹250.80 Cr)
Issue TypeBookbuilding IPO
Listing AtBSE, NSE
Share Holding Pre Issue5,68,43,250 shares
Share Holding Post Issue7,88,43,250 shares

Gujarat Kidney & Super Speciality IPO Timetable (Important Dates)

IPO Open DateMon, Dec 22, 2025
IPO Close DateWed, Dec 24, 2025
Tentative AllotmentFri, Dec 26, 2025
Initiation of RefundsMon, Dec 29, 2025
Credit of Shares to DematMon, Dec 29, 2025
Listing DateTue, Dec 30, 2025
Cut-off time for UPI mandate confirmation5 PM on Wed, Dec 24, 2025

Gujarat Kidney & Super Speciality IPO Lot Size

Bidders have the opportunity to bid for a minimum of 128 shares, with the option to increase in multiples. The table below outlines the minimum and maximum investment thresholds for both retail investors and High Net Worth Individuals (HNIs), specifying the corresponding number of shares and amounts involved.

ApplicationLotsSharesAmount
Retail (Min)1128₹14,592
Retail (Max)131,664₹1,89,696
S-HNI (Min)141,792₹2,04,288
S-HNI (Max)688,704₹9,92,256
B-HNI (Min)698,832₹10,06,848

Gujarat Kidney & Super Speciality IPO Reservation

QIB Shares OfferedNot less than 75% of the Issue
Retail Shares OfferedNot more than 10% of the Issue
NII (HNI) Shares OfferedNot more than 15% of the Issue

Gujarat Kidney & Super Speciality IPO Financial Information

Period Ended30 Jun 202531 Mar 202531 Mar 202431 Mar 2023
Assets61.5955.3420.533.87
Total Income15.2740.405.480.00
Profit After Tax5.409.501.71-0.01
EBITDA8.6316.551.95-0.01
NET Worth30.5625.7110.800.37
Reserves and Surplus19.4214.5710.600.17
Total Borrowing4.033.881.94120.35
Amount in ₹ Crore

Key Performance Indicator – Gujarat Kidney & Super Speciality IPO

KPIValues
ROE36.61%
ROCE37.65%
Debt/Equity0.15
RoNW36.61%
PAT Margin23.61%
EBITDA Margin41.12%
Price to Book Value22.62
EPS1.85
P/E (x)61.62
Promoter Holding99.10%

Prospectus Links:

Prospectus: Official documents that provide detailed information about the IPO and the company.

Scroll to Top